Original pharmaceutical and healthcare market research and pharmaceutical and healthcare sector trend analysis for the Indian pharmaceutical and healthcare industry.
Competitive intelligence,
The India Pharmaceuticals and Healthcare Report has been researched at source and features the latest available data and forecasts to 2011 covering drugs and healthcare expenditure, the prescription, OTC and generics markets, and foreign trade; company rankings and competitive landscapes including multinational and national drugs companies; and analysis of latest industry news, trends and regulatory developments.
Its India Pharmaceuticals and Healthcare Report provides industry professionals, market investors and corporate and financial services analysts with independent forecasts and competitive intelligence on the Indian pharmaceutical and healthcare industry.
Key Benefits of Report
Benchmark Its Independent 5-year Pharmaceutical and Healthcare Industry Forecasts on India to test other views – a key input for successful budgeting and strategic business planning in the Indian pharmaceutical and healthcare market.
Target Business Opportunities & Risks in the Indian Pharmaceutical and Healthcare Sector through our reviews of latest industry trends, regulatory changes and major deals, projects and investments in India.
Exploit The Latest Competitive Indian Pharmaceutical and Healthcare Intelligence & company SWOTS on your competitors and peers through company rankings by sales, market share and ownership structure – includes multi-national and national companies in India.
Coverage
Executive Summary & Industry SWOT
An at-a-glance perspective on latest regulatory developments, key forecast indicators and major corporate developments, covering the prescription, OTC and generics markets. The SWOT outlines strategic factors which affect Its forecast analysis, and taken together with Its Economic and Business Environment SWOTS, give a complete overview of market climate.
Market Summary
Outline of market characteristics, growth factors, leading therapeutic segments and a competitivness of the market.
Regulatory Regime
Guide to and analysis of country intellectual property developments and pricing & reimbursement issues, which constitute the regulatory make-up of the market.
Industry Developments
Focus on government healthcare reforms, epidemiological trends, company M&As, product launches, market entries, FDI activity, R&D and patent legislation.
It 5-Year Industry Forecast
5-Year Forecasts to end-2011 for all key industry indicators (see list below), supported by explicit assumptions, plus analysis of key downside risks to the main forecast, including:
Drug market expenditure (US$bn); drug expenditure per capita (US$); as % of gdp
Prescription drug market (US$bn)/as % of total market; sales by alimentary tract/metabolism;
OTC market (US$bn)/as % of total market (sales by analgesic, cough and cold, digestives, skin treatments, vitamins and minerals)
Generics market (US$bn)/ as % of total market
Health expenditure (US$bn, % of gdp and per capita); public sector health expenditure as % of total; number of hospitals; beds, hospital admissions, doctors, births and deaths per 000 population
Forecasts based on bespoke It economic modelling, using historical data sets of macroeconomic and industry variables to derive rigorous statistical relationships, anchored in advanced linear regression techniques.
It 5-Year Macroeconomic Forecasts
It forecasts for all headline macroeconomic indicators, including:
Nominal and real GDP, % real GDP growth, % private consumption growth, % industrial output growth, % consumer price index, % GDP price deflator, exports, imports, trade balance, current account balance, foreign direct investment, exchange rate against US$, government expenditure, external debt
Competitive Landscape & Profiles
Intelligence on the market position of major MNC power houses and indigenous companies. It profiles key research-based companies. Company SWOTS are provided for all key strategic players, complete with a company activity overview, its leading products and analysis of business opportunities.
Executive Summary
The Sector At A Glance
Key Insights On The Pharmaceutical Sector Of India
India continues to hold a significant pharmaceutical market potential, not least due to its large and rapidly expanding population. Prescription drugs account for around two-thirds of the total market, with over-thecounter (OTC) products likely to benefit from the liberalisation of retail channels anticipated during the forecast period. Generics represent less than 40% of the market by value, although intellectual property (IP) regime shortcomings allow for the production and use of counterfeit drugs. India’s imports of medicines are expected to overtake its exports, resulting in a trade deficit of US$300mn by 2010, although foreign acquisitions by large domestic generic manufacturers will boost exports of cheaper drugs. The Indian drug sector remains highly competitive, with the state pricing policy continuing to stifle growth and the new drug patent law set to increase foreign company activity.
It expects the pharmaceutical sector to grow by some 8% in 2006, behind the country’s major Asian rival, China. Sales are likely to exceed US$15.2bn by 2010, with annual growth at around 9%. The growth of ‘civilisation’
In regional terms, India will outperform a number of its neighbours, boosted by its ongoing industrial development, foreign direct investment and overseas activities. However, IP and pricing problems will continue to hinder pharmaceutical sector growth over the coming years. Indeed, the government is planning to reduce the prices of approximately 8% of all drugs sold in the country, with the most expensive treatments receiving the largest cuts. Nevertheless, Its adjusted Business Environment Rankings for Asia place India in sixth place, behind China.
Indian firms continue to expand in advanced markets, both through outright acquisitions of overseas facilities and generic product approvals in advanced markets. Most recently, Venus Remedies has secured a deal to export its oncology products to Ukraine. International companies remain interested in the Indian market, which is developing due to population growth, as well as improvements in economic conditions and patent law. Consequently, new launches will become a more frequent occurrence. USbased Bristol-Myers Squibb has recently introduced Baraclude to meet the rising, but as yet unmet, medical need for chronic hepatitis B treatment in India.
For more information kindly visit: http://www.bharatbook.com/
